Executive vice president, head of Biopharm
Ludovic Helfgott joined Novo Nordisk in April 2019 as executive vice president and head of Biopharm.
Mr Helfgott joined Novo Nordisk from AstraZeneca, where he was global vice president in charge of the company's Cardiovascular, Metabolism and Renal global franchise, supervising both assets in development and on the market. He joined AstraZeneca in 2005 in an international sales effectiveness role and has since held operational leadership roles with increasing responsibilities in Italy, Spain and at corporate headquarters. Prior to this, Mr Helfgott was with McKinsey & Company, in Paris, Moscow and Brussels from 1998 to 2005.
Mr Helfgott holds an M.B.A. from Insead, France, 2001, and is a graduate of the French Army Officer’s Academy, E.A.A.B.C, France, 1998. Moreover, Mr Helfgott holds an M.A. in Finance & Laureate of the Health Economy Chair, E.S.S.E.C, France, 1996, and an M.A. in Political and Macroeconomy, I.E.P. Paris, France, 1994.
Mr Helfgott is a French national, born July 1974.